AH50 Complement Test: Alternative Pathway Activity, Low Levels, and Immune Function

The AH50 complement test measures whether the alternative complement pathway can complete its immune-defense cascade. This pathway is part of the innate immune system, which responds quickly to microbes and helps antibodies, white blood cells, and other defenses clear infection. AH50 is most useful as a functional screening test when a clinician suspects an inherited complement deficiency, unexplained recurrent bacterial infections, abnormal complement consumption, or a problem involving complement-regulating proteins.

A low or absent AH50 result does not identify one specific disorder. Its meaning depends heavily on the CH50 result, C3 and C4 concentrations, symptoms, medications, and how the blood sample was handled. Because complement proteins can lose activity after collection, delayed processing or improper temperature control may create a falsely low value. A carefully collected repeat sample and targeted follow-up tests are often needed before a deficiency is confirmed.

• AH50 measures function, not just protein amount: It tests whether the alternative pathway can activate through the terminal membrane attack complex.
• Low AH50 with normal CH50 suggests an alternative-pathway defect: Factor B, factor D, properdin, or a regulatory protein may need evaluation.
• Low AH50 and low CH50 point to a shared or acquired problem: C3 or terminal-component deficiency, complement consumption, medication effects, or sample degradation are possibilities.
• A normal result does not exclude every complement disorder: Mild, intermittent, regulatory, or lectin-pathway abnormalities may require different tests.
• Reference ranges are laboratory specific: Results may be reported as percent normal, units per milliliter, or a qualitative category.
• No fasting is usually required: Medication timing and rapid freezing of the separated serum are more important than food intake.

Table of Contents

• What the AH50 Test Measures
• Why an AH50 Test Is Ordered
• Collection, Method, and Preparation
• Understanding Low, Normal, and High Results
• AH50 and CH50 Patterns
• Conditions That Can Change AH50
• Follow-Up After an Abnormal Result
• Limitations and When to Seek Care

What the AH50 Test Measures

AH50 stands for alternative pathway hemolytic activity at 50%. It evaluates the combined function of proteins that allow the alternative complement pathway to activate, amplify, and form the membrane attack complex. The exact laboratory method may be a traditional red-blood-cell lysis assay or a newer enzyme-based functional assay, but the clinical purpose is similar: determine whether the pathway works from its early steps through C5b-9 formation.

The complement system has three main activation routes:

• The classical pathway is commonly triggered by antibodies attached to a target.
• The lectin pathway begins when pattern-recognition proteins bind certain microbial carbohydrates.
• The alternative pathway activates continuously at a low level and becomes strongly amplified on surfaces that lack protective complement regulators.

All three routes converge at C3. They then proceed through C5 and the terminal components C6, C7, C8, and C9. Those terminal proteins assemble into the membrane attack complex, which can damage susceptible microbial membranes.

AH50 therefore depends on more than the proteins unique to the alternative pathway. It requires functional factor B, factor D, properdin, C3, C5, C6, C7, C8, and C9. It is also influenced by regulators such as factor H and factor I, which prevent uncontrolled complement activity. A major defect or severe depletion at any necessary point can reduce the measured activity.

This differs from a concentration test. A person may have a normal amount of a complement protein that does not work properly. Conversely, a mildly reduced concentration may still provide enough function for a near-normal pathway assay. AH50 is best understood as a stress test for the entire alternative pathway, while individual protein measurements answer narrower questions.

The related CH50 complement test evaluates classical-pathway and terminal-pathway function. Clinicians often order AH50 and CH50 together because the pattern between them helps locate the likely level of a defect.

Why an AH50 Test Is Ordered

Clinicians most often order AH50 when the infection history suggests that complement defense may be impaired. Complement deficiencies are uncommon, so the test is usually guided by a pattern rather than a single routine infection.

Features that may lead to testing include:

• Recurrent or unusually severe infections caused by Neisseria meningitidis or Neisseria gonorrhoeae
• Repeated invasive infections with encapsulated bacteria, especially when other immune studies are unrevealing
• Meningococcal disease occurring more than once, at an unusual age, or in several relatives
• A family history of a known complement deficiency
• Unexplained low C3, glomerulonephritis, thrombotic microangiopathy, or suspected alternative-pathway dysregulation
• Autoimmune disease accompanied by unusual infections or persistently abnormal complement results
• Monitoring of selected complement-inhibiting treatments when a functional assay is clinically appropriate

The infection pattern can hint at the affected portion of the cascade. Properdin deficiency, factor D deficiency, and some factor B defects can impair alternative-pathway defense. Deficiencies involving C5 through C9 affect the terminal pathway and are especially associated with invasive Neisseria infection. Because the terminal pathway is shared, these deficiencies usually lower both AH50 and CH50.

AH50 may also be included in the evaluation of complement-mediated kidney disease. Examples include C3 glomerulopathy and complement-mediated thrombotic microangiopathy. In these settings, however, a normal AH50 does not rule out disease, and a low result does not prove that complement dysregulation caused the kidney injury. Many patients need a broader assessment that may include C3, C4, factor H, factor I, factor B, autoantibodies, activation products, kidney biopsy findings, and genetic testing.

The test is not a general measure of whether the immune system is “strong.” Antibody production, lymphocyte function, neutrophil function, and complement activity are separate parts of immunity. Someone with recurrent infections may need an immunoglobulin panel or other immune studies even when AH50 is normal.

Collection, Method, and Preparation

AH50 uses a serum sample drawn from a vein. Fasting is generally unnecessary unless other tests collected at the same visit require it. The more important issue is preserving complement activity after the blood draw.

Complement proteins are temperature sensitive and can activate or degrade outside the body. Laboratory instructions commonly require the blood to clot under controlled conditions, prompt separation of serum from cells, and immediate freezing at a very low temperature. Some laboratories reject serum gel tubes, refrigerated samples, specimens that were not frozen promptly, or samples exposed to repeated freeze-thaw cycles.

Because procedures differ, the collection site should follow the performing laboratory’s instructions exactly. A technically poor specimen can produce low AH50 even when the patient’s complement system is normal.

Before testing, tell the ordering clinician about:

• Eculizumab, ravulizumab, zilucoplan, pegcetacoplan, iptacopan, danicopan, or any other complement-directed drug
• Recent plasma infusion, fresh frozen plasma, or plasma exchange
• A current severe infection, major surgery, trauma, or active autoimmune flare
• Significant liver disease or severe protein loss
• Previous complement results and the dates of treatment doses

Drugs that block C5 can markedly suppress both AH50 and CH50 because both assays require terminal-pathway activity. Drugs acting earlier in the alternative pathway may have a stronger effect on AH50 than on CH50. If the test is being used to assess drug effect, the timing relative to a dose must match the treating specialist’s protocol. A random result without dose timing may be hard to interpret.

Plasma-containing treatment can temporarily replace missing complement proteins and make an inherited deficiency look less severe. When the test is diagnostic rather than treatment monitoring, clinicians may plan collection before replacement therapy when medically safe.

Turnaround time ranges from several days to about two weeks because AH50 is often performed at a reference laboratory rather than on site. The report should identify the method, units, reference interval, and any comments about specimen quality.

Understanding Low, Normal, and High Results

A laboratory’s own reference interval must be used. AH50 methods are not standardized to one universal numeric range. One laboratory may report activity as a percentage of normal and consider 31% or greater within range; another may use units per milliliter or classify the result as normal, low, or absent. Values from different laboratories should not be compared as though they use the same scale.

Low or absent AH50

A low result means the sample did not generate expected alternative-pathway activity. The main possibilities are:

• An inherited deficiency of factor B, factor D, properdin, C3, or a terminal component
• A functional defect despite a measurable protein concentration
• Loss or overconsumption of complement proteins during active disease
• A regulatory abnormality involving factor H or factor I
• Suppression by a complement inhibitor
• Reduced synthesis in severe liver disease
• Protein loss through the kidneys or gastrointestinal tract
• Improper collection, transport, thawing, or storage

“Absent” activity often raises greater concern for a complete component deficiency, strong drug effect, or severely compromised specimen. It still requires confirmation. A repeat result on a properly handled sample is especially important when the clinical history does not fit.

Normal AH50

A normal result shows that the alternative and terminal pathways had enough combined activity under the assay conditions. It makes a complete deficiency of a required component less likely, but it does not exclude every complement problem.

A person may still have:

• A classical-pathway defect that lowers CH50 but leaves AH50 normal
• A lectin-pathway defect
• A partial deficiency with enough residual activity to fall within range
• An intermittent consumption process that was inactive at collection
• A regulatory or genetic variant that promotes inappropriate activation without consistently reducing pathway capacity
• A complement-mediated disease for which AH50 has limited sensitivity

A normal AH50 should therefore be interpreted alongside the reason for testing rather than treated as a universal clearance of complement disease.

High AH50

An increased AH50 is usually less diagnostically specific than a low result. Complement proteins can rise as part of an acute-phase response during inflammation, infection, or tissue injury. Laboratories and methods also differ in whether they define an upper limit.

A high value does not by itself diagnose autoimmune disease, infection, cancer, or a “hyperactive immune system.” Clinicians usually focus on symptoms and other markers rather than pursuing an isolated mild elevation. Repeated high results may be interpreted with C3, C4, C-reactive protein, liver-produced proteins, and the underlying condition.

AH50 and CH50 Patterns

The paired pattern is more informative than either assay alone. It helps separate an early classical-pathway problem from an alternative-pathway problem and from a defect in the shared terminal cascade.

AH50	CH50	Pattern most often suggests	Typical next checks
Low or absent	Normal	Alternative-pathway component or regulator defect; sometimes an alternative-pathway drug effect	Factor B, factor D, properdin, factor H, factor I, C3, repeat functional testing
Normal	Low or absent	Early classical-pathway defect involving C1, C2, or C4; classical-pathway consumption	C1 components, C2, C4, clinical evaluation for immune-complex disease
Low or absent	Low or absent	C3 or terminal-component defect, broad consumption, severe synthesis problem, drug effect, or poor specimen handling	C3, C4, C5-C9, factor H and I, medication review, repeat sample
Normal	Normal	Major complete defects in the tested pathways are less likely	Consider lectin-pathway, antibody, cellular, genetic, or disease-specific testing if suspicion remains

These patterns guide, rather than replace, diagnosis. Complement consumption can mimic inherited deficiency. For example, active immune-complex disease may lower multiple components at the same time. Measuring complement C3 and complement C4 helps distinguish some acquired patterns, although no single combination is perfect.

A low AH50 with normal CH50 often directs attention toward properdin, factor D, or complement factor B. If both functional assays are low while C3 and C4 concentrations remain normal, a terminal-component deficiency becomes more likely. In that setting, individual C5 through C9 testing can identify the affected protein.

Conditions That Can Change AH50

AH50 can be reduced by inherited absence, acquired depletion, excessive activation, treatment, or technical loss of activity. The clinical context separates these categories.

Inherited complement deficiencies

Complete alternative-pathway deficiencies are rare. Properdin deficiency is X-linked, so it mainly affects males, although female carriers can have variable findings. Factor D and factor B deficiencies are usually inherited in an autosomal recessive pattern. These disorders may present with severe meningococcal or other invasive bacterial infections.

Terminal-component deficiencies involving C5, C6, C7, C8, or C9 impair membrane attack complex formation. They typically lower both functional pathways and strongly increase susceptibility to invasive Neisseria. A C5 test or measurements of the other terminal components may follow an abnormal screening pattern.

Defects of factor H and factor I can permit uncontrolled activation and depletion of C3. Their clinical effects may include recurrent infection, C3 glomerulopathy, or complement-mediated thrombotic microangiopathy. The phenotype depends on the specific genetic or acquired abnormality; not every variant causes the same laboratory pattern.

Acquired complement consumption

Complement activity may fall when proteins are being activated faster than the liver can replace them. Possible settings include severe infection, immune-complex disease, some forms of glomerulonephritis, cryoglobulinemia, and other inflammatory disorders. Consumption often affects multiple components rather than removing one protein completely.

Acquired factor H autoantibodies can disrupt alternative-pathway control. They are associated with some cases of complement-mediated thrombotic microangiopathy and C3 glomerulopathy. AH50 alone cannot detect or exclude these antibodies.

Reduced production or excessive loss

Most complement proteins are made in the liver. Advanced liver dysfunction can reduce concentrations and functional activity. Severe nephrotic-range urinary protein loss or protein-losing enteropathy can also lower circulating immune proteins. These situations usually produce a broader laboratory picture rather than an isolated AH50 abnormality.

Complement-directed therapy

AH50 may be intentionally low during treatment. C5 inhibitors prevent completion of the terminal cascade, while factor B, factor D, and C3 inhibitors alter other steps. The desired degree of suppression depends on the drug, disease, assay, dose interval, and clinical protocol. Patients should not change or delay therapy based only on a result without guidance from the prescribing specialist.

Follow-Up After an Abnormal Result

The first step is to verify that the result is believable. The clinician reviews collection conditions, transport temperature, medication exposure, recent plasma therapy, acute illness, and prior results. A repeat AH50 and CH50 on a fresh, correctly handled specimen may prevent an extensive workup based on a preanalytical error.

When the abnormality persists, testing is chosen from the functional pattern and clinical history. Possible next steps include:

1. Repeat AH50 with CH50. Confirmation is especially important for an unexpected low or absent value.
2. Measure C3 and C4. These concentrations help identify broad consumption and provide context for pathway results.
3. Test individual alternative-pathway proteins. Factor B, factor D, properdin, factor H, and factor I may be measured by concentration or function.
4. Assess terminal components. C5, C6, C7, C8, and C9 are considered when both pathway assays are low or invasive Neisseria infection is prominent.
5. Look for acquired regulators or activation markers. Factor H autoantibodies, soluble C5b-9, nephritic factors, and disease-specific complement studies may be appropriate in kidney or thrombotic disorders.
6. Consider genetic testing. Molecular testing can confirm an inherited deficiency, clarify family risk, and identify variants affecting complement regulation.
7. Evaluate other immune systems. Quantitative immunoglobulins, vaccine antibody responses, lymphocyte subsets, and neutrophil studies may be needed when infections are not fully explained by complement.

A confirmed complement deficiency often leads to consultation with a clinical immunologist, infectious disease specialist, nephrologist, hematologist, or genetic counselor, depending on the presentation. Management may include vaccination against meningococcal, pneumococcal, and Haemophilus influenzae type b disease; rapid evaluation of fever; antibiotic prophylaxis in selected patients; and education for relatives who may also be affected.

Vaccination reduces risk but does not eliminate it, particularly in people with terminal-pathway deficiencies or those receiving complement inhibitors. Patients may need an emergency plan explaining when to seek immediate care and which symptoms should not be watched at home.

When an inherited defect is confirmed, testing relatives can be more informative than waiting for another serious infection. The approach depends on the inheritance pattern. Properdin deficiency is X-linked, while many component deficiencies are autosomal recessive. A genetic counselor can explain who may be a carrier, which relatives should receive functional or molecular testing, and how results affect children or future pregnancies. Family members should not assume that feeling well excludes a deficiency; some people remain healthy for years before their first invasive infection.

Long-term follow-up also helps separate a stable inherited pattern from fluctuating acquired consumption. A complete deficiency usually produces a reproducible functional pattern when the specimen is handled correctly. Results caused by infection, inflammation, protein loss, or treatment may change as the underlying condition changes. Keeping copies of AH50, CH50, component concentrations, medication dates, and laboratory methods gives specialists a clearer timeline and reduces unnecessary repeat testing.

Limitations and When to Seek Care

AH50 is sensitive to the integrity of the entire assay pathway, which makes it useful for screening but vulnerable to nonspecific abnormalities. It cannot reliably distinguish inherited absence from acquired consumption, identify the exact defective protein, or prove that complement caused a patient’s symptoms.

Common interpretation errors include:

• Comparing a number with a reference range from a different laboratory
• Assuming every low result represents a genetic deficiency
• Ignoring C5-inhibitor or alternative-pathway-inhibitor treatment
• Ruling out all complement disease after one normal result
• Diagnosing complement-mediated kidney disease from AH50 alone
• Failing to repeat an unexpected result after questionable handling
• Treating a mildly high result as a specific disease marker

Urgent medical care is warranted for symptoms that may signal meningococcal disease or sepsis, including sudden fever, severe headache, stiff neck, confusion, rapidly spreading purple or red spots, severe weakness, fast breathing, or cold mottled limbs. People with known terminal complement deficiency or complement-inhibitor treatment should follow their emergency plan even if they have been vaccinated.

Prompt assessment is also needed for possible thrombotic microangiopathy, such as markedly reduced urine output, new swelling, unusual bruising, severe fatigue, neurologic symptoms, or high blood pressure during an acute illness. These symptoms have many causes, but delayed evaluation can be dangerous.

For a stable outpatient with an isolated low AH50 and no severe symptoms, the usual response is not panic. It is a structured review of specimen quality, medications, CH50, component concentrations, infection history, and targeted follow-up testing. That process turns a broad functional signal into a clinically meaningful answer.

References

• Immunodeficiency: Complement disorders 2024 (Review)
• Alternative Pathway Diagnostics 2023 (Review)
• Inherited defects in the complement system 2022 (Review)
• Complements and Their Role in Systemic Disorders 2024 (Review)
• Complement Testing – Complement Deficiency and Anticomplement Therapeutic Response Monitoring 2025 (Official Guidance)
• Alternative Complement Pathway Activity (AH50) 2026 (Laboratory Test Guidance)

Disclaimer

AH50 results require interpretation by a qualified healthcare professional using the performing laboratory’s range, the CH50 pattern, clinical history, medications, and specimen conditions. This information is educational and is not a diagnosis or a substitute for individualized medical care. Seek urgent evaluation for symptoms of meningitis, sepsis, or sudden kidney and neurologic problems.